Metagenomi, Inc. (MGX)
NASDAQ: MGX · IEX Real-Time Price · USD
4.230
-0.190 (-4.30%)
Jul 2, 2024, 4:00 PM EDT - Market closed
Metagenomi Revenue
Revenue in the quarter ending March 31, 2024 was $11.16M with 99.45% year-over-year growth. In the year 2023, Metagenomi had annual revenue of $44.76M with 160.21% growth.
Revenue (ttm)
$44.76M
Revenue Growth
+160.21%
P/S Ratio
3.35
Revenue / Employee
$199,401
Employees
237
Market Cap
158.47M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 44.76M | 27.56M | 160.21% |
Dec 31, 2022 | 17.20M | 16.96M | 6,978.19% |
Dec 31, 2021 | 243.00K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionMGX News
- 4 weeks ago - Metagenomi to Present at the 2024 Jefferies Global Healthcare Conference - GlobeNewsWire
- 7 weeks ago - Metagenomi Presents Data at Scientific Conferences and First Quarter 2024 Financial Results - GlobeNewsWire
- 2 months ago - Metagenomi to regain full development rights to its wholly-owned base editing and RIGS systems - GlobeNewsWire
- 3 months ago - Metagenomi to Present at Upcoming Scientific Meetings - GlobeNewsWire
- 3 months ago - Metagenomi Reports Business Updates and Full Year 2023 Financial Results - GlobeNewsWire
- 4 months ago - Metagenomi to Participate in the 44th Annual Cowen Healthcare Conference - GlobeNewsWire
- 5 months ago - Metagenomi Announces Closing of Initial Public Offering - GlobeNewsWire
- 5 months ago - Moderna, Bayer-backed Metagenomi stock drops 32% on Nasdaq debut - Reuters